We are live on ! Find out more
AH

Aviva Holdings Portfolio holdings

AUM $20.5M
1-Year Est. Return 117.01%
This Fund
S&P 500
This Quarter Est. Return
+13.94%
1 Year Est. Return
+117.01%
3 Year Est. Return
-36.54%
5 Year Est. Return
-22.08%
10 Year Est. Return
–
AUM
$616M
AUM Growth
+$369M
Cap. Flow
+$63.2M
Cap. Flow %
10.26%
Top 10 Hldgs %
100%
Holding
7
New
1
Increased
2
Reduced
–
Closed
1

Top Buys

Rank Stock Value
1
ESPR
Esperion Therapeutics
ESPR
+$52.2M
2
MDCO
Medicines Co
MDCO
+$13.2M
3
SLDB icon
Solid Biosciences
SLDB
+$236K

Top Sells

Rank Stock Value
1
PTCT icon
PTC Therapeutics
PTCT
+$2.36M

Sector Composition

Rank Sector Weight
1 Healthcare 58.59%
2 Miscellaneous 41.41%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRTX
1
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$155M 25.1%
3,135,966
– –
MDCO
2
DELISTED
Medicines Co
MDCO
$139M 22.51%
3,778,742
+405,345
+12% +$13.2M
ESPR
3
DELISTED
Esperion Therapeutics
ESPR
$47M 7.64%
1,200,100
+1,032,513
+616% +$52.2M
MGNX icon
4
MacroGenics
MGNX
$263M
$20.2M 3.28%
977,426
– –
SLDB icon
5
Solid Biosciences
SLDB
$1.09B
$409K 0.07%
+766
New +$236K
PTCT icon
6
PTC Therapeutics
PTCT
$5.98B
– –
-87,330
Closed -$2.36M

Similar funds

MFAM
M Financial Asset Management Portland, Oregon $20.6M AUM 4.99% 1-Year Est. Return
SL
Stevard LLC Chicago, Illinois $26.8M AUM 42.43% 1-Year Est. Return
CIM
Cowen Investment Management New York $12M AUM 1.47% 1-Year Est. Return
SFM
Spartan Fund Management Toronto, Ontario, Canada $30M AUM 11.98% 1-Year Est. Return
SFG
Susquehanna Financial Group Bala Cynwyd, Pennsylvania $10.9M AUM
CGI
Calixto Global Investors Coral Gables, Florida $30.7M AUM 111.27% 1-Year Est. Return
VFA
Virtus Fund Advisers Hartford, Connecticut $32.1M AUM 39.5% 1-Year Est. Return
AMG
Ace Management Global Sao Paulo, Brazil $7.88M AUM 47.04% 1-Year Est. Return

Aviva Holdings's Q2 2018 Portfolio in Review

As of Q2 2018, Aviva Holdings held 7 positions worth $616M, up 150% from $246M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Aviva Holdings deployed $63.2M of net new capital in Q2 2018, opening 1 new position and adding to 2 existing holdings. Its largest new stake was Solid Biosciences: 766 shares worth $409K.

By sector, the portfolio is most concentrated in Healthcare at 59% of assets, down from 100% a quarter earlier, followed by Miscellaneous.

On the sell side, the most notable exit was PTC Therapeutics, an estimated $2.36M sold.

  • Aviva Holdings's largest Q2 2018 buy was Solid Biosciences: 766 shares worth $409K.
  • Aviva Holdings added most to Esperion Therapeutics in Q2 2018, an estimated $52.2M increase.
  • Aviva Holdings fully exited PTC Therapeutics in Q2 2018, selling an estimated $2.36M.
  • Aviva Holdings's ten largest holdings make up 100% of its $616M portfolio in Q2 2018.
  • Aviva Holdings opened 1 new position and closed 1 in Q2 2018.
  • Aviva Holdings's portfolio value rose 150% quarter-over-quarter to $616M.

Based on Aviva Holdings's 13F filing for Q2 2018, filed 14 Aug 2018.